Table 5.
OR with 95% CI of developing MS for subjects with different combinations of anti-EBNA-1 status and IM history compared to subjects with low anti-EBNA-1 antibody levels without IM history (relative access proportion due to interaction, RERI).
| Anti-EBNA-1 antibody levels | IM history | ca/coa | OR (95% CI)b | OR (95% CI)c |
|---|---|---|---|---|
| Low | – | 1,067/2,445 | 1.0 (reference) | 1.0 (reference) |
| Low | + | 168/220 | 1.8 (1.4–2.2) | 1.8 (1.5–2.3) |
| High | – | 3,440/2,484 | 3.2 (2.9–3.5) | 3.2 (2.9–3.5) |
| High | + | 641/282 | 5.2 (4.4–6.1) | 5.2 (4.4–6.1) |
| RERI 1.2 (0.3–2.0) |
a
Number of exposed cases and controls.
b
Adjusted for age, gender, residential area, study, and ancestry.
c
Adjusted for age, gender, residential area, study, ancestry, smoking, adolescent BMI, DRB1*15:01, DRB1*03:01, DRB1*13:03, DRB1*08:01, A*02:01, B*44:02, B*38:01, B*55:01, DQA1*01:01, DQB1*03:01, and DQB1*03:02.